These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 19686597)

  • 21. [Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab-a comparison of SF-36 and SF-12].
    Haibel H; Niewerth M; Brandt J; Rudwaleit M; Listing J; Sieper J; Braun J
    Z Rheumatol; 2004 Oct; 63(5):393-401. PubMed ID: 15517300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
    Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
    Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex.
    Law L; Beckman Rehnman J; Deminger A; Klingberg E; Jacobsson LTH; Forsblad-d'Elia H
    Arthritis Res Ther; 2018 Dec; 20(1):284. PubMed ID: 30587228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.
    Huang F; Gu J; Zhu P; Bao C; Xu J; Xu H; Wu H; Wang G; Shi Q; Andhivarothai N; Anderson J; Pangan AL
    Ann Rheum Dis; 2014 Mar; 73(3):587-94. PubMed ID: 23475983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
    Boonen A; Patel V; Traina S; Chiou CF; Maetzel A; Tsuji W
    J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC;
    Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.
    Bao C; Huang F; Khan MA; Fei K; Wu Z; Han C; Hsia EC
    Rheumatology (Oxford); 2014 Sep; 53(9):1654-63. PubMed ID: 24729398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients.
    Madsen OR; Rytter A; Hansen LB; Suetta C; Egsmose C
    Clin Rheumatol; 2010 Aug; 29(8):849-54. PubMed ID: 20306214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial.
    Reveille JD; Hwang MC; Danve A; Kafka S; Peterson S; Lo KH; Kim L; Hsia EC; Chan EKH; Deodhar A
    Clin Rheumatol; 2021 Apr; 40(4):1331-1341. PubMed ID: 32926247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.
    Revicki DA; Menter A; Feldman S; Kimel M; Harnam N; Willian MK
    Health Qual Life Outcomes; 2008 Oct; 6():75. PubMed ID: 18831744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.
    Paramarta JE; De Rycke L; Heijda TF; Ambarus CA; Vos K; Dinant HJ; Tak PP; Baeten DL
    Ann Rheum Dis; 2013 Nov; 72(11):1793-9. PubMed ID: 23139265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.
    Papp KA; Signorovitch J; Ramakrishnan K; Yu AP; Gupta SR; Bao Y; Mulani PM
    Clin Drug Investig; 2011; 31(1):51-60. PubMed ID: 20932070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.
    Gladman DD; Mease PJ; Cifaldi MA; Perdok RJ; Sasso E; Medich J
    Ann Rheum Dis; 2007 Feb; 66(2):163-8. PubMed ID: 17046964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-Related Quality of Life in Patients with Ankylosing Spondylitis: Relationship with Disease-Related Variables.
    Elolemy G; Aboughanima A; Ganeb S; Elziat H
    Curr Rheumatol Rev; 2020; 16(4):311-318. PubMed ID: 31656154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis.
    Navarro-Compán V; Baraliakos X; Magrey M; Östör A; Saffore CD; Mittal M; Song IH; Ganz F; Stigler J; Deodhar A
    Rheumatol Ther; 2023 Jun; 10(3):679-691. PubMed ID: 36820984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of life and related variables in patients with ankylosing spondylitis.
    Bodur H; Ataman S; Rezvani A; Buğdaycı DS; Cevik R; Birtane M; Akıncı A; Altay Z; Günaydın R; Yener M; Koçyiğit H; Duruöz T; Yazgan P; Cakar E; Aydın G; Hepgüler S; Altan L; Kırnap M; Olmez N; Soydemir R; Kozanoğlu E; Bal A; Sivrioğlu K; Karkucak M; Günendi Z
    Qual Life Res; 2011 May; 20(4):543-9. PubMed ID: 20978859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom.
    Botteman MF; Hay JW; Luo MP; Curry AS; Wong RL; van Hout BA
    Rheumatology (Oxford); 2007 Aug; 46(8):1320-8. PubMed ID: 17545684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.